For the Inventor, By the Inventor

Enter assignee name

South San Francisco, CA, United States of America

Oxigene, Inc.

USPTO Granted Patents = 25

% Expired Patents = 20.0

CIPO Patents = 1

EPO Patents = 2

Forward Citations = 100

Loading Chart...

Loading Chart...

35 inventors (with patents filed for the assignee):

David J Chaplin (13 out of 16 patents)

Ronald W Pero (12 out of 24 patents)

Kevin G Pinney (10 out of 22 patents)

4. Klaus Edvardsen (8 out of 10 patents)

5. Joseph Anthony Prezioso (7 out of 7 patents)

6. Charles Manly Garner, Iii (4 out of 4 patents)

7. Robert Ronald Kane (4 out of 6 patents)

8. Zhi Chen (3 out of 12 patents)

9. Vani P Mocharla (3 out of 6 patents)

10. David I Sherris (2 out of 6 patents)

11. Mallinath Hadimani (2 out of 3 patents)

12. James Michael Dorsey (2 out of 6 patents)

13. Alan N Schwartz (1 out of 34 patents)

14. Francis Lee (1 out of 21 patents)

15. Kishore Kumar Gaddale Devanna (1 out of 3 patents)

Core Competencies:

Functionalized Stilbene Derivatives

Vascular Targeting Agents

Hematopoietic Neoplasms

Tubulin Binding Ligands

Prodrug Constructs

Therapeutic Activity

Tumor Growth Modulation

Nicotinamide Derivatives

Carotenoid Compositions

Chemosensitizers

Drug Resistance

25 patents: Sort by Forward Citations

1. RE45907 - Functionalized stilbene derivatives as improved vascular targeting agents (2016-02-29),

2. RE45720 - Functionalized stilbene derivatives as improved vascular targeting agents (2015-10-05),

3. 9040500 - Method for treating hematopoietic neoplasms (2015-05-26),

4. 8877967 - Compositions and methods for inhibition of cathepsins (2014-11-04),

5. 8198302 - Compositions and methods with enhanced therapeutic activity (2012-06-12),

6. 7456214 - Chromene-containing compounds with anti-tubulin and vascular targeting activity (2008-11-25),

7. 7384925 - Functionalized stilbene derivatives as improved vascular targeting agents (2008-06-10),

8. 7358236 - Control of acute hypertension and cardiotoxicity in patients treated with vascular targeting agents (2008-04-15),

9. 7091240 - Tubulin binding ligands and corresponding prodrug constructs (2006-08-15),

10. 7037906 - Methods for modulating tumor growth and metastasis (2006-05-02),

11. 7001926 - Tubulin binding agents and corresponding prodrug constructs (2006-02-21),

12. 6956054 - Compositions and methods for use in targeting vascular destruction (2005-10-18),

13. 6919324 - Functionalized stilbene derivatives as improved vascular targeting agents (2005-07-19),

14. 6743937 - Efficient method of synthesizing combretastatin A-4 prodrugs (2004-06-01),

15. 6713517 - Use of aryl N-substituted carboxamides directly and as radio-and chemosensitizers for killing tumor and cancer cells and novel compounds for such use (2004-03-30),

Oxigene, Inc. is a biotechnology company based in South San Francisco, California, specializing in the development of innovative therapies for cancer treatment. The company focuses on advancing its proprietary drug candidates that target the tumor microenvironment, aiming to improve patient outcomes through enhanced efficacy and reduced side effects. With a commitment to scientific excellence, Oxigene leverages cutting-edge research to address unmet medical needs in oncology, contributing to the evolving landscape of cancer therapeutics.

Profile summary based on public USPTO records.

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

25 Patents

#53 in South San Francisco, CA

#3,154 in California

#13,350 in US

#25,681 in the World

South San Francisco, CA, United States of America

Oxigene, Inc.

Forward Citations = 100

35 inventors:

David J Chaplin (13 out of 16 patents)

Ronald W Pero (12 out of 24 patents)

Kevin G Pinney (10 out of 22 patents)

4. Klaus Edvardsen (8 out of 10 patents)

5. Joseph Anthony Prezioso (7 out of 7 patents)

Please report any incorrect information to [email protected]

Loading…